Follows adults with lymphoma in France to study outcomes over time
Collects real-life health information from adults with several types of lymphoma in France.
Plain-language title generated from the registry record
Registry title: REal World Data in LYmphoma and Survival in Adults
Key facts
- Where
- Arras, Besançon, Bordeaux, Bourgoin, Caen, Chambéry, Clermont-Ferrand, Créteil, Dijon, Dunkirk, Grenoble, La Roche-sur-Yon, La Tronche, Le Mans, Libourne, Lille, Limoges, Lyon, Montpellier, Mulhouse, Nantes, Niort, Paris, Pessac, Pierre-Bénite, Poitiers, Rennes, Roubaix, Rouen, Saint-Brieuc, Saint-Cloud, Saint-Priest-en-Jarez, Strasbourg, Toulouse, and Vannes, FranceSee the 37 sites
Where in France
- Unité d'Hématologie Clinique, CH D'ARRASArras, FranceTaking people
- Service d'Hématologie, CHU Jean MinjozBesançon, FranceTaking people
- Institut BergonieBordeaux, FranceTaking people
- Service d'Onco-radiolothérapie, Polyclinique Bordeaux Nord AquitaineBordeaux, FranceTaking people
- Centre Hospitalier Pierre OudotBourgoin, FranceTaking people
- Service d'Hématologie, Institut d'Hématologie de Basse NormandieCaen, FranceTaking people
- METROPOLE SAVOIE - SITE CHAMBERY, place Lucien Biset,Chambéry, FranceTaking people
- Service d'Hématologie Clinique et de Thérapie Cellulaire, Hôpital Estaing, CHU de Clermont-FerrandClermont-Ferrand, FranceTaking people
- Unité Hémopathies Lymphoïdes, Hôpital Henri MondorCréteil, FranceTaking people
- CHU François MitterrandDijon, FranceTaking people
- Service Hématologie, Centre Hospitalier de DunkerqueDunkirk, FranceTaking people
- Service Oncologie médicale, Groupe Hospitalier Mutualiste de Grenoble, Institut Daniel Hollard,Grenoble, FranceTaking people
- CHD VendéeLa Roche-sur-Yon, FranceTaking people
- Service d'Hématologie Clinique, Centre Hospitalier Universitaire MichallonLa Tronche, FranceTaking people
- Clinique Victor HugoLe Mans, FranceTaking people
- Centre hospitalier LibourneLibourne, FranceTaking people
- Service des maladies du sang, Hôpital Claude Huriez, CHRU de LilleLille, FranceTaking people
- Service Oncologie médicale, HOPITAL SAINT VINCENT-DE-PAULLille, FranceTaking people
- Service Hématologie Clinique et Thérapie Cellulaire, CHU DE LIMOGES - HOPITAL DUPUYTREN,Limoges, FranceTaking people
- Département d'Hématologie et Oncologie, Centre Léon BérardLyon, FranceTaking people
- Département d'Hématologie Clinique, Hôpital Saint-Eloi,Montpellier, FranceTaking people
- Service Hématologie, GH REGION MULHOUSE ET SUD ALSACE - HOPITAL EMILE MULLER,Mulhouse, FranceTaking people
- Service d'Hématologie clinique, Centre Hospitalier Universitaire de NantesNantes, FranceTaking people
- Centre Hospitalier de NiortNiort, FranceTaking people
- Service Hématologie, Hôpital St LouisParis, FranceTaking people
- CHU Haut LevequePessac, FranceTaking people
- Centre Hospitalier Lyon-SudPierre-Bénite, FranceTaking people
- Service d'Hématologie et Thérapie Cellulaire, Centre Hospitalier Universitaire de PoitiersPoitiers, FranceTaking people
- Hématologie Clinique, CHU PONTCHAILLOURennes, FranceTaking people
- Service Hématologie, Centre Hospitalier de Roubaix - Hôpital Victor ProvoRoubaix, FranceTaking people
- Service Hématologie, UNIVERSITE DE ROUEN, CENTRE HENRI BECQUERELRouen, FranceTaking people
- Service Hématologie, CH YVES LE FOLLSaint-Brieuc, FranceTaking people
- Service Hématologie, Institut Curie - Hôpital René HUGUENINSaint-Cloud, FranceTaking people
- Département d'Hématologie Clinique et Thérapie Cellulaire, Institut de Cancérologie Lucien NeuwirthSaint-Priest-en-Jarez, FranceTaking people
- Hopitaux Universitaires de StrasbourgStrasbourg, FranceTaking people
- Institut universitaire du cancerToulouse, FranceTaking people
- Hématologie Clinique, CH DE BRETAGNE ATLANTIQUEVannes, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Hospices Civils de Lyon
- Trial code
- NCT03869619
- Record updated
- 28 June 2021
- Original description
REALYSA cohort is a population-based epidemiological platform in real-life for lymphomas designed to enrich prognostic data, by integrating together epidemiological, clinical and biological data.Read full original descriptionShow less
REAL WORLD DATA IN LYMPHOMA AND SURVIVAL IN ADULTS
REALYSA cohort is a population-based epidemiological platform in real-life for lymphomas designed to enrich prognostic data, by integrating together epidemiological, clinical and biological data.
REALYSA is a platform perfectly set up to
* Study prognostic factors using integrated epidemiological and biological data (genetics), to better characterize the determinants of refractoriness and relapse in patients with lymphoma, to follow the growing number of survivors and describe median to long-term sequela, second cancer, quality of life (QoL)… * Document treatment effectiveness in real life and observance * Address socio-economical questions
Inclusion: Signature of the consent form for participation in the REALYSA cohort; Aged over 18 at the time of inclusion; Diagnosed with lymphoma in the last 6 months (180 days); Lymphoma subtype belonging to at least one of the 7 histological subtypes: diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma, T-cell lymphoma, Hodgkin's lymphoma, Burkitt lymphoma.
Exclusion: Anti-lymphoma treatment already received (except pre-phase: typically corticosteroids, vincristine, cyclophosphamide, etoposide, alone or in combination); Documented HIV infection; Any other lymphoma subtype not included in the list in Appendix 1. Of note, are excluded:; Chronic lymphocytic leukemia/small lymphocytic lymphoma; Hairy cell leukemia and variant; Lymphoplasmacytic lymphoma; Waldenström macroglobulinemia; Primary DLBCL of the central nervous system (CNS); T-cell large granular lymphocytic leukemia; Chronic lymphoproliferative disorder of NK cells; Mycosis fungoides; Sézary syndrome; Primary cutaneous T cell lymphomas (mainly diagnosed and treated by dermatologists); Post-transplant lymphoproliferative disorders (PTLD).